Freeport-McMoRan Inc vs GeneDx Holdings Corp — how do they compare? Freeport-McMoRan Inc trades at $59.44 (market cap $87.65B), while GeneDx Holdings Corp trades at $65.6 (market cap $1.96B). The key difference: Freeport-McMoRan Inc is far larger — about 44.7× GeneDx Holdings Corp's market cap, and Freeport-McMoRan Inc pays a 0.98% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| FCX | WGS | |
|---|---|---|
Market Cap | $87.65B | $1.96B |
Sector | Basic Materials | Technology |
52-Week High | $71.73 | $167.51 |
52-Week Low | $35.34 | $34.51 |
Enterprise Value | $94.31B | $1.96B |
Dividend Yield | 0.98% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings Corp. (WGS) trades at $65.785, up 5.37% today, but faces a bearish technical signal with the stock near resistance at $65. The company shows mixed fundamentals with strong revenue growth to $427.54M in 2025 but a net loss of -$21.02M, while analyst consensus remains bullish with a $75.40 price target. Recent news highlights multiple class-action lawsuits alleging securities fraud tied to a 49% stock decline and acquisition underperformance, creating significant investor uncertainty.
The outlook is highly conflicted: strong analyst buy ratings and recent earnings beats contrast with deepening losses, negative cash flow projections for 2026, and legal overhangs. Key risks include litigation outcomes, profitability challenges, and execution missteps, but the stock offers potential upside if the company can stabilize margins and resolve legal issues amid high institutional skepticism.
Trailing returns across standard periods
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →